Structure Therapeutics Inc. American Depositary Shares GPCR

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

• Zacks Investment Research 23 sept

  Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

  Novo Nordisk received positive regulatory recommendations in Europe for Frehemgo (hemophilia A treatment) and Sogroya (growth hormone therapy for multiple indications), potentially diversifying revenue beyond its pressured GLP-1 portfolio. However, the company faces intensifying competition from Eli Lilly's blockbuster GLP-1 drugs and smaller biotechs, with Novo's stock underperforming the industry year-to-date.

  

• Zacks Investment Research 17 sept

  LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

  Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However, the stock trades at a premium 26.3x forward earnings amid intensifying competition from Novo Nordisk and smaller biotechs in the oral GLP-1 market. Analysts recommend existing investors hold while new investors consider accumulating on market corrections.

  

• Zacks Investment Research 8 sept

  Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

  Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.